Biotechnology annual review最新文献_第8页

Horseradish peroxidase: a valuable tool in biotechnology. 辣根过氧化物酶:一种有价值的生物技术工具。

Biotechnology annual review Pub Date : 2003-01-01 DOI: 10.1016/s1387-2656(03)09003-3

Ana M Azevedo, Verónica C Martins, Duarte M Prazeres, Vojislav Vojinović, Joaquim M Cabral, Luís P Fonseca

{"title":"Horseradish peroxidase: a valuable tool in biotechnology.","authors":"Ana M Azevedo, Verónica C Martins, Duarte M Prazeres, Vojislav Vojinović, Joaquim M Cabral, Luís P Fonseca","doi":"10.1016/s1387-2656(03)09003-3","DOIUrl":"https://doi.org/10.1016/s1387-2656(03)09003-3","url":null,"abstract":"Peroxidases have conquered a prominent position in biotechnology and associated research areas (enzymology, biochemistry, medicine, genetics, physiology, histo- and cytochemistry). They are one of the most extensively studied groups of enzymes and the literature is rich in research papers dating back from the 19th century. Nevertheless, peroxidases continue to be widely studied, with more than 2000 articles already published in 2002 (according to the Institute for Scientific Information). The importance of peroxidases is emphasised by their wide distribution among living organisms and by their multiple physiological roles. They have been divided into three superfamilies according to their source and mode of action: plant peroxidases, animal peroxidases and catalases. Among all peroxidases, horseradish peroxidase (HRP) has received a special attention and will be the focus of this review. A brief description of the three super-families is included in the first section of this review. In the second section, a comprehensive description of the present state of knowledge of the structure and catalytic action of HRP is presented. The physiological role of peroxidases in higher plants is described in the third section. And finally, the fourth section addresses the applications of peroxidases, especially HRP, in the environmental and health care sectors, and in the pharmaceutical, chemical and biotechnological industries.","PeriodicalId":79566,"journal":{"name":"Biotechnology annual review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s1387-2656(03)09003-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24104490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 253

Clinical trial methods to discover and validate predictive markers for treatment response in cancer. 发现和验证癌症治疗反应预测标志物的临床试验方法。

Biotechnology annual review Pub Date : 2003-01-01 DOI: 10.1016/s1387-2656(03)09005-7

Soonmyung Paik

引用次数: 22

Production of high-quality marketing applications: strategies for biotechnology companies working with contract research organizations. 生产高质量的市场应用:生物技术公司与合同研究机构合作的策略。

Biotechnology annual review Pub Date : 2003-01-01 DOI: 10.1016/s1387-2656(03)09006-9

Sandra J Hecker, Christopher Preston, MaryAnn Foote

引用次数: 4

The state of biopharmaceutical manufacturing. 生物制药生产的现状。

Biotechnology annual review Pub Date : 2003-01-01 DOI: 10.1016/s1387-2656(03)09008-2

David T Molowa, Rosemary Mazanet

引用次数: 39

The development of supportive-care agents for patients with cancer. 癌症患者支持治疗药物的开发。

Biotechnology annual review Pub Date : 2003-01-01 DOI: 10.1016/s1387-2656(03)09011-2

Theresa K Neumann, MaryAnn Foote

引用次数: 1

Review of current authorship guidelines and the controversy regarding publication of clinical trial data. 当前作者指南的回顾和关于临床试验数据发表的争议。

Biotechnology annual review Pub Date : 2003-01-01 DOI: 10.1016/s1387-2656(03)09009-4

MaryAnn Foote

引用次数: 9

Considerations for the planning and conduct of reproducibility studies of in vitro diagnostic tests for infectious agents. 规划和进行传染性原体外诊断试验可重复性研究的考虑。

Biotechnology annual review Pub Date : 2003-01-01 DOI: 10.1016/s1387-2656(03)09004-5

Toniann Derion

{"title":"Considerations for the planning and conduct of reproducibility studies of in vitro diagnostic tests for infectious agents.","authors":"Toniann Derion","doi":"10.1016/s1387-2656(03)09004-5","DOIUrl":"https://doi.org/10.1016/s1387-2656(03)09004-5","url":null,"abstract":"The US Food and Drug Administration (FDA) requires reproducibility studies for premarket approval of in vitro diagnostic (IVD) tests. Results of reproducibility studies provide an estimate of the variability of the IVD test among study sites, reagent lots, site operators, within a single test run, and over multiple test days. In planning the study, discuss the product registration strategy, including the intended use of the product and desired label claims, and define the study team. Design the sample panel according to the limit of detection or quantitation of the test, dynamic range of the test, FDA guidelines, sample matrix, and genotype. Consider legal and ethical issues for obtaining the panel parent specimen, such as minimizing the privacy risk and keeping promises to donors. During the study, review data promptly to determine invalid runs, discover trends in the data that may require additional operator training, ensure correct completion of case report forms, and resolve queries quickly. At the end of the study, gather the study team to review and improve processes. Use the outcome to set expectations of other functional areas and to provide product feedback.","PeriodicalId":79566,"journal":{"name":"Biotechnology annual review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s1387-2656(03)09004-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24104491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases. 血管靶向治疗癌症和慢性炎症性疾病的研究进展。

Biotechnology annual review Pub Date : 2002-01-01 DOI: 10.1016/s1387-2656(02)08007-9

Astrid J Schraa, Maaike Everts, Robbert J Kok, Sigridur A Asgeirsdóttir, Dirk K F Meijer, Lou F M H de Leij, Grietje Molema

引用次数: 23

Protein formulation and fill-finish operations. 蛋白质配方和补全操作。

Biotechnology annual review Pub Date : 2002-01-01 DOI: 10.1016/s1387-2656(02)08004-3

Sugunakar Y Patro, Erwin Freund, Byeong S Chang

{"title":"Protein formulation and fill-finish operations.","authors":"Sugunakar Y Patro, Erwin Freund, Byeong S Chang","doi":"10.1016/s1387-2656(02)08004-3","DOIUrl":"https://doi.org/10.1016/s1387-2656(02)08004-3","url":null,"abstract":"One of the challenges for the successful commercialization of therapeutic proteins is to maintain the safety and efficacy of the protein during the manufacturing process, storage, and administration. To achieve this, the purified form of the protein drug is usually \"formulated\" with carefully selected excipients. The operations that occur subsequent to protein purification, such as freezing of the purified protein bulk, thawing of the bulk, formulation (excipient addition), sterile filtration, filling, freeze-drying, and inspection are commonly referred as \"formulation and fill-finish operations\". This review is focused on the protein formulation and fill-finish operations, critical process parameters at each operation, and the process considerations required for maintaining safety and efficacy of the drug during manufacturing and storage. Since proteins have complex molecular structures that can influence the protein stability, the reader is first introduced to salient concepts related to protein structure. This is followed by a review of the possible protein-degradation mechanisms and how a variety of external factors can contribute to protein degradation during the in vitro processing of the protein drug. The reader is then introduced to each of the formulation and fill-finish operations mentioned above, the possible degradations during each unit-operation, and process considerations necessary to avoid those degradations.","PeriodicalId":79566,"journal":{"name":"Biotechnology annual review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s1387-2656(02)08004-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22116546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 87

New chips for molecular biology and diagnostics. 用于分子生物学和诊断学的新芯片。

Biotechnology annual review Pub Date : 2002-01-01 DOI: 10.1016/s1387-2656(02)08005-5

Nathalie Zammatteo, Sandrine Hamels, Françoise De Longueville, Isabelle Alexandre, Jean-luc Gala, Francis Brasseur, José Remacle

引用次数: 38